Eszter Lazar-Molnar
No Rating Available
(Learn About Our Rating System)

Eszter Lazar-Molnar, PhD, D(ABMLI), F(ACHI)

Languages spoken: Hungarian, English

Dr. Lazar-Molnar is an Associate Professor in the Department of Pathology at the University of Utah School of Medicine. She is the director of the Histocompatibility and Immunogenetics laboratory at University of Utah Health, and medical director in the Immunology division at ARUP Laboratories.

She is board certified by the American Board of Medical Laboratory Immunology (ABMLI), and is a Fellow of the American College of Histocompatibility and Immunogenetics (ACHI).

Dr. Lazar-Molnar’s primary interest is diagnostic laboratory immunology, including transplantation testing for pre- and post-transplant monitoring, HLA-disease, and HLA-pharmacogenetic associations, and test interference by monoclonal antibody therapeutics.

Specialties

Board Certification

American Board of Medical Laboratory Immunology
American College of Histocompatibility & Immunogenetics (ACHI)

Board Certification and Academic Information

Academic Departments Pathology -Associate Professor (Clinical)
Board Certification
American Board of Medical Laboratory Immunology
American College of Histocompatibility & Immunogenetics (ACHI)

Education history

Fellowship Immunology - University of Utah Clinical Fellow
Postdoctoral Fellowship Microbiology & Immunology - Albert Einstein College of Medicine Postdoctoral Fellow
Doctoral Training Genetics, Cell and Immunobiology - Semmelweis University School of Medicine Ph.D.
Doctoral Training Pharmacy - University of Medicine and Pharmacy of Târgu Mureș Pharm.D.

Selected Publications

Journal Article

  1. Yamauchi J, Fornadi K, Raghavan D, Jweehan D, Oygen S, Marineci S, Pole A, Jain D, Lazar-Molnar E, Molnar MZ (2026). Early posttransplant rituximab use in kidney transplant recipients with preexisting donor-specific antibodies. Ren Fail, 48(1), 2620179.
  2. Lzr-Molnr E, Truax CM, Eiting MM, Jain D, Hurst D, Zukauckas K, Pearce A, Bergam S, Gardner S, Clayton F, Florido R, Stehlik J, Shah KS (2025). First use of imlifidase desensitization in a highly sensitized heart and liver transplant candidate: A case report. Hum Immunol, 86(5), 111584.
  3. Jain D, Pavlov IY, unik S, Delgado JC, Lzr-Molnr E (2025). Expanding the clinical utility of reporter gene assay to infliximab biosimilars. Clin Chim Acta, 575, 120337.
  4. Charnaya O, Ishaque T, Hallett A, Morris GP, Coppage M, Schmitz JL, Timofeeva O, Lzr-Molnr E, Zhang A, Krummey S, Hidalgo L, Segev DL, Tambur AR, Massie AB (2024). The Impact of HLA-DQαβ Heterodimer Mismatch on Living Donor Kidney Allograft Outcomes. Transplantation, 109(4), 720-728.
  5. Al-Rabadi LF, Storey A, Larsen CP, Hassen SI, Revelo MP, Singh RS, Lazar-Molnar E, Jain D, Ibrahim A, Darras F, Salam R, Al-Rabadi A, Wikan N, Redecke V, Talwar M, Haecker H, Beck LH Jr, Caza TN (2024). De novo Membranous Nephropathy in Renal Allografts is Associated With Protocadherin FAT1. Kidney Int Rep, 10(1), 247-251.
  6. Sideris K, Lzr-Molnr E, Kyriakopoulos CP, Taleb I, Hurst D, Ugolini S, Selzman CH, Brinker L, Drakos SG, Tonna JE, Geer L, Goodwin ML, Wever-Pinzon O, Hanff TC, Fang JC, Carter S, Stehlik J (2024). Bridge-to-transplant temporary mechanical circulatory support and risk of allosensitization. Clin Transplant, 38(5), e15330.
  7. Jain D, Pido MTJ, Delgado JC, Willrich MAV, Lzr-Molnr E (2023). Comparison of Two Clinical Laboratory Assays for Measuring Serum Adalimumab and Antibodies to Adalimumab. J Appl Lab Med, 8(6), 1054-1064.
  8. Potter S, Sudarshan D, Lzr-Molnr E, Baker S, Metcalf RA, Lin L (2022). Life threatening platelet transfusion refractoriness due to an anamnestic human leukocyte antigen alloantibody response. Transfusion, 62(11), 2161-2162.
  9. Profaizer T, Dibb K, Bethers H, Monds C, Andreasen J, Delgado JC, Lzr-Molnr E (2021). Comparison of Next-Generation Sequencing-Based Human Leukocyte Antigen Typing with Clinical Flow Cytometry and Allele-Specific PCR Melting Assays for HLA-B27 Genotyping. J Appl Lab Med, 6(5), 1221-1227.
  10. Luo YR, Chakraborty I, Lazar-Molnar E, Wu AHB, Lynch KL (2020). Development of Label-Free Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and Antidrug Antibodies. Clin Chem, 66(10), 1319-1328.
  11. Profaizer T, Pole A, Monds C, Delgado JC, Lzr-Molnr E (2020). Clinical utility of next generation sequencing based HLA typing for disease association and pharmacogenetic testing. Hum Immunol, 81(7), 354-360.
  12. Ravkov EV, Charlton CM, Barker AP, Hill H, Peterson LK, Slev P, Tebo A, Voelkerding KV, Wittwer CT, Heikal N, Delgado JC, Lzr-Molnr E, Kumnovics A (2019). Evaluation of Mass Cytometry in the Clinical Laboratory. Cytometry B Clin Cytom, 96(4), 266-274.
  13. Pavlov IY, Parker RL, Lzr-Molnr E, Strathmann FG, Delgado JC (2019). Inductively coupled plasma mass spectrometry assay for quantification of free infliximab in serum. J Immunol Methods, 470, 33-39.
  14. Yang Y, Wysocki E, Antwi K, Niederkofler E, Leung EKY, Lazar-Molnar E, Yeo KJ (2018). Development and validation of a targeted affinity-enrichment and LC-MS/MS proteomics approach for the therapeutic monitoring of adalimumab. Clin Chim Acta, 483, 308-314.
  15. Willrich MAV, Lazar-Molnar E, Snyder MR, Delgado JC (2018). Comparison of clinical laboratory assays for measuring serum infliximab and antibodies for infliximab. J Appl Lab Med, 2(6), 893-903.
  16. Profaizer T, Lzr-Molnr E, Pole A, Delgado JC, Kumnovics A (2017). HLA genotyping using the Illumina HLA TruSight next-generation sequencing kits: A comparison. Int J Immunogenet, 44(4), 164-168.
  17. Lzr-Molnr E, Scandiuzzi L, Basu I, Quinn T, Sylvestre E, Palmieri E, Ramagopal UA, Nathenson SG, Guha C, Almo SC (2017). Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. EBioMedicine, 17, 30-44.
  18. Lzr-Molnr E, Delgado JC (2016). Immunogenicity Assessment of Tumor Necrosis Factor Antagonists in the Clinical Laboratory. Clin Chem, 62(9), 1186-98.
  19. Profaizer T, Lzr-Molnr E, Close DW, Delgado JC, Kumnovics A (2016). HLA genotyping in the clinical laboratory: comparison of next-generation sequencing methods. HLA, 88(1-2), 14-24.
  20. Pavlov IY, Carper J, Lzr-Molnr E, Delgado JC (2016). Clinical laboratory application of a reporter-gene assay for measurement of functional activity and neutralizing antibody response to infliximab. Clin Chim Acta, 453, 147-53.
  21. Lazar-Molnar E, Tebo AE (2014). Autoimmune NMDA receptor encephalitis. Clin Chim Acta, 438, 90-7.
  22. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015). Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med, 21(1), 24-33.
  23. Scandiuzzi L, Ghosh K, Hofmeyer KA, Abadi YM, Lzr-Molnr E, Lin EY, Liu Q, Jeon H, Almo SC, Chen L, Nathenson SG, Zang X (2014). Tissue-expressed B7-H1 critically controls intestinal inflammation. Cell Rep, 6(4), 625-32.
  24. Arora P, Baena A, Yu KO, Saini NK, Kharkwal SS, Goldberg MF, Kunnath-Velayudhan S, Carreo LJ, Venkataswamy MM, Kim J, Lazar-Molnar E, Lauvau G, Chang YT, Liu Z, Bittman R, Al-Shamkhani A, Cox LR, Jervis PJ, Veerapen N, Besra GS, Porcelli SA (2014). A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. Immunity, 40(1), 105-16.
  25. Vigdorovich V, Ramagopal UA, Lzr-Molnr E, Sylvestre E, Lee JS, Hofmeyer KA, Zang X, Nathenson SG, Almo SC (2013). Structure and T cell inhibition properties of B7 family member, B7-H3. Structure, 21(5), 707-17.
  26. Lzr-Molnr E, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J, Porcelli SA, Almo SC, Nathenson SG, Jacobs WR Jr (2010). Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A, 107(30), 13402-7.
  27. Chattopadhyay K, Lazar-Molnar E, Yan Q, Rubinstein R, Zhan C, Vigdorovich V, Ramagopal UA, Bonanno J, Nathenson SG, Almo SC (2009). Sequence, structure, function, immunity: structural genomics of costimulation. Immunol Rev, 229(1), 356-86.
  28. Lzr-Molnr E, Yan Q, Cao E, Ramagopal U, Nathenson SG, Almo SC (2008). Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci U S A, 105(30), 10483-8.
  29. Shi L, Albuquerque PC, Lazar-Molnar E, Wang X, Santambrogio L, Gcser A, Nosanchuk JD (2008). A monoclonal antibody to Histoplasma capsulatum alters the intracellular fate of the fungus in murine macrophages. Eukaryot Cell, 7(7), 1109-17.
  30. Lzr-Molnr E, Gcser A, Freeman GJ, Almo SC, Nathenson SG, Nosanchuk JD (2008). The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum. Proc Natl Acad Sci U S A, 105(7), 2658-63.
  31. Lazar-Molnar E, Almo SC, Nathenson SG (2006). The interchain disulfide linkage is not a prerequisite but enhances CD28 costimulatory function. Cell Immunol, 244(2), 125-9.
  32. Lzr-Molnr E, Hegyesi H, Pllinger E, Kovcs P, Tth S, Fitzsimons C, Cricco G, Martin G, Bergoc R, Darvas Z, Rivera ES, Falus A (2002). Inhibition of human primary melanoma cell proliferation by histamine is enhanced by interleukin-6. Eur J Clin Invest, 32(10), 743-9.
  33. Szincsk N, Hegyesi H, Hunyadi J, Martin G, Lzr-Molnr E, Kovcs P, Rivera E, Falus A, Juhsz I (2002). Cimetidine and a tamoxifen derivate reduce tumour formation in SCID mice xenotransplanted with a human melanoma cell line. Melanoma Res, 12(3), 231-40.
  34. Falus A, Hegyesi H, Lzr-Molnr E, Ps Z, Lszl V, Darvas Z (2001). Paracrine and autocrine interactions in melanoma: histamine is a relevant player in local regulation. Trends Immunol, 22(12), 648-52.
  35. Lzr-Molnr E, Hegyesi H, Tth S, Falus A (2000). Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine, 12(6), 547-54.
  36. Horvath B, Heninger E, Hegyesi H, Lazar E, Radvany Z, Szalai C, Darvas Z, Falus A (2000). Reciprocal inhibitory interactions between interferon gamma and histamine in melanoma. Inflamm Res, 49 Suppl 1, S27-8.
  37. Kohidai L, Kovacs P, Lazar-Molnar E, Csaba G (2000). Presence, uptake and localization of an immunoreactively interleukin 6 (IL-6)-like molecule in Tetrahymena pyriformis. Cell Biol Int, 24(10), 749-55.

Review

  1. Lzr-Molnr E, Peterson LK (2025). Clinical utility of the lymphocyte proliferation assay, an in vitro functional readout of the adaptive immune response. [Review]. J Immunol Methods, 537, 113819.
  2. Profaizer T, Lazar-Molnar E (2022). Quantifying Donor-Derived Cell-Free DNA in Solid Organ Transplant Recipients. ASHI Quarterly, 2022, Volume 46, Number 2. [Review]. ASHI Quarterly, 46(2).
  3. Profaizer T, Lazar-Molnar E (2020). Cell-Free DNA and its Applications in Laboratory Medicine. ASHI Quarterly, 2020, Volume 44, Number 2, pg22. [Review]. ASHI Quarterly, 44(2), 22.
  4. Lzr-Molnr E, Delgado JC (2019). Implications of Monoclonal Antibody Therapeutics Use for Clinical Laboratory Testing. [Review]. Clin Chem, 65(3), 393-405.
  5. Lazar-Molnar E, Snyder M (2018). The Role of Human Leukocyte Antigen in Celiac Disease Diagnostics. [Review]. Clin Lab Med, 38(4), 655-668.
  6. Lazar-Molnar E, Delgado JC (2016). Immunogenicity Assessment of Tumor Necrosis Factor Antagonists in the Clinical Laboratory. [Review]. Clin Chem, 62(9), 1186-98.
  7. Molnar EL, Hegyesi H, Toth S, Darvas Z, Laszlo V, Szalai C, Falus A (2000). Biosynthesis of interleukin-6, an autocrine growth factor for melanoma, is regulated by melanoma-derived histamine. [Review]. Semin Cancer Biol, 10(1), 25-8.

Book Chapter

  1. Jain D, Lazar-Molnar E (2026). Chapter 18. Human Leukocyte Antigen (HLA) Testing. In Weijie Li (Ed.), Laboratory Assessments of Pediatric Leukemia. Springer Nature Switzerland AG.
  2. Lazar-Molnar E, Willrich MA, Delgado JC (2023). Monoclonal Antibody Therapeutics and Immunogenicity. In Rifai, Chiu, Young, Burnham, and Wittwer (Eds.), Tietz Textbook of Laboratory Medicine (7th Edition).
  3. Kumnovics A, Lazar-Molnar E, Delgado JC (2021). The Major Histocompatibility Complex and Disease. In McPherson RA, Pincus MR (Eds.), Henry's Clinical Diagnosis and Management by Laboratory Methods (24th). Elsevier.
  4. Lazar-Molnar E (2004). Signal-transduction pathways of histamine receptors. In Falus A (Ed.), Histamine: Biology and Medical Aspects. Budapest: SpringMed Publishing Ltd.

Editorial

  1. Delgado JC, Lazar-Molnar E (2018). HLA in Transplantation and Beyond. Clin Lab Med, 38(4), xi-xii.

Patent

  1. Lazar-Molnar E, Almo SC (2014). A Selective High-Affinity Immune Stimulatory Reagent And Uses Thereof, International Patent No. PCT/US2014/15235. U.S. Patent No. WO 2014124217 A1. Washington, D.C.:U.S. Patent and Trademark Office.